全文获取类型
收费全文 | 17052篇 |
免费 | 1835篇 |
国内免费 | 459篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 328篇 |
妇产科学 | 220篇 |
基础医学 | 843篇 |
口腔科学 | 179篇 |
临床医学 | 2122篇 |
内科学 | 2998篇 |
皮肤病学 | 597篇 |
神经病学 | 896篇 |
特种医学 | 323篇 |
外国民族医学 | 3篇 |
外科学 | 1070篇 |
综合类 | 1482篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 1706篇 |
眼科学 | 213篇 |
药学 | 4867篇 |
65篇 | |
中国医学 | 563篇 |
肿瘤学 | 820篇 |
出版年
2024年 | 37篇 |
2023年 | 654篇 |
2022年 | 745篇 |
2021年 | 1204篇 |
2020年 | 1339篇 |
2019年 | 1081篇 |
2018年 | 921篇 |
2017年 | 853篇 |
2016年 | 742篇 |
2015年 | 727篇 |
2014年 | 1300篇 |
2013年 | 1415篇 |
2012年 | 992篇 |
2011年 | 1042篇 |
2010年 | 867篇 |
2009年 | 726篇 |
2008年 | 715篇 |
2007年 | 654篇 |
2006年 | 501篇 |
2005年 | 396篇 |
2004年 | 345篇 |
2003年 | 356篇 |
2002年 | 217篇 |
2001年 | 194篇 |
2000年 | 142篇 |
1999年 | 132篇 |
1998年 | 93篇 |
1997年 | 92篇 |
1996年 | 93篇 |
1995年 | 83篇 |
1994年 | 63篇 |
1993年 | 68篇 |
1992年 | 78篇 |
1991年 | 91篇 |
1990年 | 70篇 |
1989年 | 43篇 |
1988年 | 47篇 |
1987年 | 48篇 |
1986年 | 44篇 |
1985年 | 24篇 |
1984年 | 20篇 |
1983年 | 12篇 |
1982年 | 15篇 |
1981年 | 18篇 |
1980年 | 7篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 11篇 |
1976年 | 5篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
《Vaccine》2022,40(41):5997-6000
Coronavirus disease 2019 (COVID-19) vaccine administration started in February 2021 in Japan. As of December 2021, approximately 75% of the population aged ≥12 years had received two doses of vaccine. We conducted a study to investigate vasovagal reactions (VVR) after COVID-19 vaccination using data on adverse events following immunization. The crude reporting rate of VVR (cases/1,000,000 doses) after vaccination was 9.6 in all age groups combined, and was more frequent in the younger age groups: 28.6 and 37.2 in individuals aged 10–19 years and 20–29 years, respectively. In individuals aged 10–29 years, the rate was similar in males and females (33.0 and 34.2, respectively, p = 0.53); but was higher after dose 1 than after dose 2 (57.4 and 8.8, respectively, p < 0.001). Based on these results, caution needs to be exercised when vaccinating adolescents and young adults, especially with dose 1 of COVID-19 vaccines. 相似文献
23.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1199-1206
PurposeTo compare the technical success of antegrade uteral stent (AUS) and retrograde ureteral stent (RUS) placements in patients with malignant ureteral obstruction (MUO) and to determine the predictors of technical failure of RUS.Materials and MethodsThis study retrospectively included 61 AUS placements (44 patients) performed under fluoroscopic guidance and 76 RUS placements (55 patients) performed under cystoscopic guidance in patients with MUO from January 2019 to December 2020. Technical success rates of the 2 techniques were compared using inverse probability of treatment weighting (IPTW) analysis. Logistic regression was used to identify predictive factors for technical failures.ResultsTechnical success was achieved in 98.4% of the AUS group and 47.4% of the RUS group. After stabilized IPTW, the technical success rate was higher in the AUS group than in the RUS group (adjusted risk difference, 49.4%; 95% confidence interval [CI], 35.4%–63.1%). The independent predictors for technical failure of the RUS procedure were age of ≥65 years (odds ratio [OR], 5.56; 95% CI, 1.73–21.27), ureteral orifice invasion (OR, 4.21; 95% CI, 1.46–13.46), and extrinsic cancer (OR, 15.58; 95% CI, 2.92–111.81).ConclusionsThe technical success rate of AUS placement was higher than that of RUS placement in patients with MUO. RUS failure was associated with age of ≥65 years, cancer with ureteral orifice invasion, and extrinsic ureteral obstruction. 相似文献
24.
Anqi Wang Yan Xu Yunyun Fei Mengzhao Wang 《Asia-Pacific Journal of Clinical Oncology》2020,16(4):201-210
The advent of immune checkpoint inhibitors has improved survival in some types of cancer and brought promising prospects to cancer immunotherapy. Despite their clinical benefits, significant off‐target toxicities resulting from the immune system activation have been observed, namely immune‐related adverse events (irAEs), which pose to clinicians a new challenge of optimal management. With steroids being the mainstay of current management of irAEs, immunosuppressive agents are especially indicated for severe or steroid‐refractory cases, based on current immunopathophysiological knowledge and on extrapolations of treatment options for primary autoimmune disorders. This review focuses on the status and recent clinical progress of immunosuppressive agents in the management of severe and steroid‐refractory irAEs. 相似文献
25.
刘艳 《中国继续医学教育》2020,(10):174-176
目的 探究PDCA循环在皮肤科护理管理中的应用效果.方法 纳入医院皮肤科2017年8月—2018年10月间的患者,共100例,计算机筛选后分为对照组和观察组,均有50例,在治疗期间前者接受常规护理,后者采取PDCA循环管理护理,比对护理满意度、并发症、生活质量和瘙痒情况.结果 不良反应发生率[观察组(4.00%)vs.对照组(18.00%)],P<0.05;护理满意度[观察组(98.00%)vs.对照组(80.00%)],P<0.05;观察组各维度的生活质量评分值均显著高于对照组,P<0.05;瘙痒程度评估观察组显著低于对照组,P<0.05.结论 在皮肤科护理管理中采取PDCA循环管理,可改善患处皮肤状况,提升患者的舒适度,提高其生活质量,整体提升护理的水平. 相似文献
26.
ABSTRACT
Introduction
Acne is a chronic, inflammatory, and immune mediated disease of pilosebaceous unit, highly prevalent in adolescents. It involves face, trunk, and back; may leave scars and affect quality of life. Early, effective, and safe treatment is the key for disease resolution. Oral isotretinoin is the unique treatment for cure or prolonged remission for moderate and severe acne, preventing psychosocial impact and scars. It inhibits sebaceous glands activity and has anti-inflammatory and immunoregulatory properties. 相似文献27.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
28.
随着免疫检查点抑制剂(immune checkpoint inhibitors,ICPI)在国内外临床试验和应用中的逐步推广,越来越多的患者从免疫治疗中获得显著的疗效。其中抗程序细胞死亡蛋白1(programmed death-1,PD-1)及其配体(PD-1 ligand,PD-L1)免疫检查点抑制剂已被美国食品药品管理局(FDA)批准用于恶性黑色素瘤、转移性鳞状非小细胞肺癌、晚期肾癌、头颈鳞状细胞癌、尿路上皮癌等肿瘤的治疗。但PD-1/PD-L1单抗也会引起免疫相关性皮肤、消化道、肝脏、内分泌、肺部等器官的不良反应,皮肤毒性如皮疹、白癜风、皮肤干燥症等是最常见也是最早发生的不良反应。 相似文献
29.
Clinicians have the choice of five approved tyrosine kinase inhibitors (TKI) to select from for chronic phase CML patients. The best frontline drug for each patient and decisions about if and when to change to another TKI or to stop therapy need to be considered in the context of the comorbidities present. These issues are explored in three illustrative cases. The predominant toxicity issue for all of the TKIs except imatinib is vascular occlusive events, so a systematic approach to assessing 相似文献
Discussion
The excellent long-term outcomes achieved in most CML patients has led to a revision of the goals of therapy.13 While preventing progression to blast crisis remains an important goal, avoiding organ toxicity may be equally important, since deaths from causes other than CML are much more common than CML-related deaths. Patients most at risk of organ toxicity are those patients with comorbidities, particularly those patients with comorbidities that increase their risk of vascular events.References
- 1.Saußele S, Krauß MP, Hehlmann R, Lauseker M, Proetel U et al, Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126:42-49.
- 2.Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30:1044–1054.
- 3.Castagnetti F, Gugliotta G, Breccia M,
30.
Seulbi Lee Hyesook Park Soontae Kim Eun-Kyung Lee Jiyoung Lee Young Sun Hong Eunhee Ha 《International journal of hygiene and environmental health》2019,222(3):533-540